Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we?

References

• Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016 Feb 18;pii:S0016-5085(16)00222-5. Epub ahead of print. DOI: 10.1053/j.gastro.2016.02.031
   Web of Science ®Google Scholar
• Longstreth GF, Wilson A, Knight K. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol. 2003;98:600–607.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367:1626–1635.
   PubMed Web of Science ®Google Scholar
• Barbara G. IBS: biomarkers for IBS: ready for prime time? Nat Rev Gastroenterol Hepatol. 2015;12:9–10.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Katzka DA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1075–G1084.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
   PubMed Web of Science ®Google Scholar
• Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5:463–466.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One. 2015;10:e0126438.
   PubMed Web of Science ®Google Scholar
• Riddle MS, Murray JA, Cash BD, et al. Pathogen-specific risk of celiac disease following bacterial causes of foodborne illness: a retrospective cohort study. Dig Dis Sci. 2013;58:3242–3245.
   PubMed Web of Science ®Google Scholar
• Sabayan B, Foroughinia F, Imanieh MH. Can Campylobacter jejuni play a role in development of celiac disease? A hypothesis. World J Gastroenterol. 2007;13:4784–4785.
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:834–842.
   PubMed Web of Science ®Google Scholar
• Mujagic Z, Tigchelaar EF, Zhernakova A, et al. A novel biomarker panel for irritable bowel syndrome and the application in the general population. Sci Rep. 2016;6:26420.
   PubMed Web of Science ®Google Scholar
• Hughes PA, Zola H, Penttila IA, et al. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol. 2013;108:1066–1074.
   PubMed Web of Science ®Google Scholar
• Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37.
   PubMed Web of Science ®Google Scholar
• Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137:1425–1434.
   PubMed Web of Science ®Google Scholar
• Han W, Wang Z, Lu X, et al. Protease activated receptor 4 status of mast cells in post-infectious irritable bowel syndrome. Neurogastroenterol Motil. 2012;24:113–119, e82.
   PubMed Web of Science ®Google Scholar
• Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913–920.
   PubMed Web of Science ®Google Scholar
• Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130:304–311.
   PubMed Web of Science ®Google Scholar
• Jonefjäll B, Öhman L, Simrén M, et al. IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being. Inflamm Bowel Dis. 2016;22:2630–2640.
   PubMed Web of Science ®Google Scholar
• Vicario M, González-Castro AM, Martínez C, et al. Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut. 2015;64:1379–1388.
   PubMed Web of Science ®Google Scholar
• Bennet SM, Polster A, Törnblom H, et al. Global cytokine profiles and association with clinical characteristics in patients with irritable bowel syndrome. Am J Gastroenterol. 2016;111:1165–1176.
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Neal KR, et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2003;18:77–84.
   PubMed Web of Science ®Google Scholar
• Tuteja AK, Fang JC, Al-Suqi M, et al. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome–a pilot study. Scand J Gastroenterol. 2012;47:1159–1164.
   PubMed Web of Science ®Google Scholar
• Corinaldesi R, Stanghellini V, Cremon C, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther. 2009;30:245–252.
   PubMed Web of Science ®Google Scholar
• Lam C, Tan W, Leighton M, et al. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut. 2016;65:91–99.
   PubMed Web of Science ®Google Scholar
• Barbara G, Cremon C, Annese V, et al. Randomised controlled trial of mesalazine in IBS. Gut. 2016;65:82–90.
   PubMed Web of Science ®Google Scholar
• Spiller R. Serotonin and GI clinical disorders. Neuropharmacology. 2008;55:1072–1080.
   PubMed Web of Science ®Google Scholar
• Park JH, Rhee PL, Kim G, et al. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2006;18:539–546.
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in post-infectious IBS. Gastroenterology. 2003;125:1651–1659.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Gundersen D, Ostgaard H, et al. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci. 2012;57:873–878.
   PubMed Web of Science ®Google Scholar
• Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol. 2011;106:1290–1298.
   PubMed Web of Science ®Google Scholar
• Thijssen AY, Mujagic Z, Jonkers DM, et al. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther. 2016;43:272–282.
   PubMed Web of Science ®Google Scholar
• Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2006;130:34–43.
   PubMed Web of Science ®Google Scholar
• Rajilić-Stojanović M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792–1801.
   PubMed Web of Science ®Google Scholar
• Jeffery IB, O’Toole PW, Öhman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61:997–1006.
   PubMed Web of Science ®Google Scholar
• Malinen E, Rinttilä T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100:373–382.
   PubMed Web of Science ®Google Scholar
• Tap J, Derrien M, Törnblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2016 Oct 7; pii: S0016-5085(16)35174-5. Epub ahead of print. DOI:10.1053/j.gastro.2016.09.049 .
   Web of Science ®Google Scholar
• Casén C, Vebø HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42:71–83.
   PubMed Web of Science ®Google Scholar
• Dlugosz A, Nowak P, D’Amato M, et al. Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2015;27:1747–1754.
   PubMed Web of Science ®Google Scholar
• O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551.
   PubMed Web of Science ®Google Scholar
• Mortensen PB, Andersen JR, Arffmann S, et al. Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran. Scand J Gastroenterol. 1987;22:185–192.
   PubMed Web of Science ®Google Scholar
• Ringel-Kulka T, Choi CH, Temas D, et al. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol. 2015;110:1339–1346.
   PubMed Web of Science ®Google Scholar
• Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:512–519, e.115.
   PubMed Web of Science ®Google Scholar
• Dior M, Delagrèverie H, Duboc H, et al. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterol Motil. 2016;28:1330–1340.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Gores GJ. Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol. 2015;309:G209–G215.
   PubMed Web of Science ®Google Scholar
• Walters JR, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009;7:1189–1194.
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2012;10:1009–1015, e3.
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:1270–1275, e1.
   PubMed Web of Science ®Google Scholar
• Wedlake L, A’Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30:707–717.
   PubMed Web of Science ®Google Scholar
• Valentin N, Camilleri M, Altayar O, et al. Biomarkers for bile acid diarrhea in functional bowel disorder with diarrhea: a systematic review and meta-analysis. Gut. 2015 Sep 7;pii:gutjnl-2015-309889. Epub ahead of print. DOI: 10.1136/gutjnl-2015-309889
   Web of Science ®Google Scholar
• Gracie DJ, Kane JS, Mumtaz S, et al. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil. 2012;24:983–e538.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Acosta A, Busciglio I, et al. Effect of colesevelam on fecal bile acids and bowel functions in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:438–448.
   PubMed Web of Science ®Google Scholar
• Ohman L, Stridsberg M, Isaksson S, et al. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol. 2012;107:440–447.
   PubMed Web of Science ®Google Scholar
• El-Salhy M, Lomholt-Beck B, Hausken T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 2010;45:1435–1439.
   PubMed Web of Science ®Google Scholar
• Sidhu R, McAlindon ME, Leeds JS, et al. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. J Gastrointest Liver Dis. 2009;18:23–26.
   PubMed Web of Science ®Google Scholar
• Von Arnim U, Wex T, Ganzert C, et al. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol. 2016;9:97–103.
   PubMed Web of Science ®Google Scholar
• Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444–454.
   PubMed Web of Science ®Google Scholar
• Kawabata A, Matsunami M, Sekiguchi F. Gastrointestinal roles for proteinase-activated receptors in health and disease. Br J Pharmacol. 2008;153(Suppl 1.):S230–S240.
   PubMed Web of Science ®Google Scholar
• Vergnolle N. The enteric nervous system in inflammation and pain: the role of proteinase-activated receptors. Can J Gastroenterol. 2003;17:589–592.
   PubMed Web of Science ®Google Scholar
• Valdez-Morales EE, Overington J, Guerrero-Alba R, et al. Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2. Am J Gastroenterol. 2013;108:1634–1643.
   PubMed Web of Science ®Google Scholar
• Cenac N, Bautzova T, Le Faouder P, et al. Quantification and potential functions of endogenous agonists of transient receptor potential channels in patients with irritable bowel syndrome. Gastroenterology. 2015;149:433–444.
   PubMed Web of Science ®Google Scholar
• Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58:196–201.
   PubMed Web of Science ®Google Scholar
• Gecse K, Róka R, Ferrier L, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut. 2008;57:591–599.
   PubMed Web of Science ®Google Scholar
• Wang P, Chen FX, Du C, et al. Increased production of BDNF in colonic epithelial cells induced by fecal supernatants from diarrheic IBS patients. Sci Rep. 2015;5:10121.
   PubMed Web of Science ®Google Scholar
• Róka R, Rosztóczy A, Leveque M, et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007;5:550–555.
   PubMed Web of Science ®Google Scholar
• Tooth D, Garsed K, Singh G, et al. Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit. Gut. 2014;63:753–760.
   PubMed Web of Science ®Google Scholar
• Le Gall G, Noor SO, Ridgway K, et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res. 2011;10:4208–4218.
   PubMed Web of Science ®Google Scholar
• Ponnusamy K, Choi JN, Kim J, et al. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol. 2011;60:817–827.
   PubMed Web of Science ®Google Scholar
• Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F, et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes. 2016;7:397–441.
   PubMed Web of Science ®Google Scholar
• McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2016 Mar 14; pii: gutjnl-2015-311339. Epub ahead of print. DOI:10.1136/gutjnl-2015-311339
   Web of Science ®Google Scholar
• Hong YS, Hong KS, Park MH, et al. Metabonomic understanding of probiotic effects in humans with irritable bowel syndrome. J Clin Gastroenterol. 2011;45:415–425.
   PubMed Web of Science ®Google Scholar
• Nullens S, Nelsen T, Camilleri M. Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation. Gut. 2012;61:1132–1139.
   PubMed Web of Science ®Google Scholar
• Grotz RL, Pemberton JH, Zinsmeister AR, et al. Discriminant value of psychological distress, symptom profiles, and segmental colonic dysfunction in outpatients with severe idiopathic constipation. Gut. 1994;35:798–802.
   PubMed Web of Science ®Google Scholar
• Törnblom H, Van Oudenhove L, Sadik R, et al. Colonic transit time and IBS symptoms: what’s the link? Am J Gastroenterol. 2012;107:754–760.
   PubMed Web of Science ®Google Scholar
• Kolar GJ, Camilleri M. Prevalence of colonic motor or evacuation disorders in patients presenting with chronic nausea and vomiting evaluated by a single gastroenterologist in a tertiary referral practice. Neurogastroenterol Motil. 2014;26:131–138.
   PubMed Web of Science ®Google Scholar
• Manabe N, Wong BS, Camilleri M. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil. 2010;22:293–e82.
   PubMed Web of Science ®Google Scholar
• Deiteren A, Camilleri M, Bharucha AE. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil. 2010;22:415–423, e95.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Shin A, Busciglio I. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil. 2014;26:1677–1685.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. Aliment Pharmacol Ther. 2015;42:818–822.
   PubMed Web of Science ®Google Scholar
• Park SY, Burton D, Busciglio I, et al. Regional colonic transit pattern does not conclusively identify evacuation disorders in constipated patients with delayed colonic transit. J Neurogastroenterol Motil. 2016 Sep 25. Epub ahead of print. DOI:10.5056/jnm16066
   Web of Science ®Google Scholar
• Sabate JM, Veyrac M, Mion F, et al. Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:484–490.
   PubMed Web of Science ®Google Scholar
• Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995;109:40–52.
   PubMed Web of Science ®Google Scholar
• Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008;6:772–778.
   PubMed Web of Science ®Google Scholar
• Grinsvall C, Törnblom H, Tack J, et al. Psychological factors selectively upregulate rectal pain perception in hypersensitive patients with irritable bowel syndrome. Neurogastroenterol Motil. 2015;27:1772–1782.
   PubMed Web of Science ®Google Scholar
• Harraf F, Schmulson M, Saba L, et al. Subtypes of constipation predominant irritable bowel syndrome based on rectal perception. Gut. 1998;43:388–394.
   PubMed Web of Science ®Google Scholar
• Delvaux M. Alterations of sensorimotor functions of the digestive tract in the pathophysiology of irritable bowel syndrome. Best Pract Res Clin Gastroenterol. 2004;18:747–771.
   PubMed Web of Science ®Google Scholar
• Naliboff BD, Berman S, Suyenobu B, et al. Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology. 2006;131:352–365.
   PubMed Web of Science ®Google Scholar
• Dorn SD, Palsson OS, Thiwan SI, et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut. 2007;56:1202–1209.
   PubMed Web of Science ®Google Scholar
• Wouters MM, Balemans D, Van Wanrooy S, et al. Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016;150:875–887.
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46:421–431.
   PubMed Web of Science ®Google Scholar
• Doyle LA, Sepehr GJ, Hamilton MJ. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol. 2014;38:832–843.
   PubMed Web of Science ®Google Scholar
• Liao XJ, Mao WM, Wang Q, et al. MicroRNA-24 inhibits serotonin reuptake transporter expression and aggravates irritable bowel syndrome. Biochem Biophys Res Commun. 2016;469:288–293.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Costinean S, Croce CM, et al. MicroRNA 29 targets nuclear factor-B-repressing factor and Claudin 1 to increase intestinal permeability. Gastroenterology. 2015;148:158–169, e8.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Souba WW, Croce CM, et al. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut. 2010;59:775–784.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Yang L, Larson S, et al. Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1. Gut. 2016;65:797–805.
   PubMed Web of Science ®Google Scholar
• Fourie NH, Peace RM, Abey SK, et al. Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome. Exp Mol Pathol. 2014;96:422–425.
   PubMed Web of Science ®Google Scholar
• Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59:1213–1221.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol. 2012;303:G775–G785.
   PubMed Web of Science ®Google Scholar
• Li L, Xiong L, Yao J, et al. Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome. Dig Liver Dis. 2016;48:880–887.
   PubMedGoogle Scholar
• Grover M, Camilleri M, Hines J. C-mannitol as a novel biomarker for measurement of intestinal permeability. Neurogastroenterol Motil. 2016;28:1114–1119.
   PubMed Web of Science ®Google Scholar
• Basra S, Verne GN, Zhou Q. 902 Randomized Placebo-Controlled Trial of Glutamine for the Treatment of Diarrhea-Predominant IBS. Gastroenterology. 2013;144(Suppl. 5):S160.
   Google Scholar
• Irimia A, Labus JS, Torgerson CM. Altered viscerotopic cortical innervation in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2015;27:1075–1081.
   PubMed Web of Science ®Google Scholar
• Labus JS, Gupta A, Coveleskie K. Sex differences in emotion-related cognitive processes in irritable bowel syndrome and healthy control subjects. Pain. 2013;154:2088–2099.
   PubMed Web of Science ®Google Scholar
• Hong JY, Kilpatrick LA, Labus JS. Sex and disease-related alterations of anterior insula functional connectivity in chronic abdominal pain. J Neurosci. 2014;34:14252–14259.
   PubMed Web of Science ®Google Scholar
• Lowén MB, Mayer EA, Sjöberg M. Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome. Aliment Pharmacol Ther. 2013;37:1184–1197.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Ringel Y, Vogt BA. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology. 2003;124:754–761.
   PubMed Web of Science ®Google Scholar
• Han X, Tong J, Zhang J. Imipramine treatment improves cognitive outcome associated with enhanced hippocampal neurogenesis after traumatic brain injury in mice. J Neurotrauma. 2011;28:995–1007.
   PubMed Web of Science ®Google Scholar
• Jones MP, Chey WD, Singh S, et al. A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther. 2014;39:426–437.
   PubMed Web of Science ®Google Scholar
• Spiller RC, Humes DJ, Campbell E, et al. The patient health questionnaire 12 somatic symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther. 2010;32:811–820.
   PubMed Web of Science ®Google Scholar
• Sood R, Gracie DJ, Law GR, et al. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther. 2015;42:491–503.
   PubMed Web of Science ®Google Scholar
• Degen LP, Phillips SF. How well does stool form reflect colonic transit? Gut. 1996;39:109–113.
   PubMed Web of Science ®Google Scholar